Agreement made

TOMI Environmental Solutions, Inc. (“TOMI”), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, announced two recent sales in the Life Sciences sector, underscoring the Company’s successful strategic expansion in the sector and growth potential.

The first purchase agreement, signed with one of the largest private pharmaceutical companies in the world, includes the acquisition of a SteraMist Environment System and TOMI validation services for the client’s vivarium facility in Mexico. This landmark contract strengthens TOMI’s long-standing relationship with the company in the United States and expands TOMI’s footprint in its global operations, highlighting the Company’s ability to scale and support international partners.

The second purchase agreement arises from the Company’s collaboration with a trusted partner with decades of experience in big pharma. This partnership facilitated the sale of the first Hybrid System to Indigo Pharmaceutical, Inc. as announced in September 2023.

Continuing this momentum, the partner has now successfully sold another SteraMist Hybrid System to BeSpoke Pharmaceuticals, a Nevada-based manufacturer targeting 503B products. This advanced turnkey custom installation, valued at over $200,000, exemplifies TOMI’s innovative solutions and expanding market reach.

“These two wins represent the significant progress TOMI is making in expanding our reach and capabilities within the pharmaceutical industry, reinforcing the Company’s potential for long-term growth,” says Elissa J. (E.J.) Shane, chief operating officer of TOMI. “Building and expanding our presence within these large companies is a strategic priority for the Company. With the broad array of product offerings we provide, we are confident in our ability to meet and exceed our customers' needs. Furthermore, the partnerships we have cultivated, including consultants, designers, and contractors for new facilities around the world, are critical to this expansion. These relationships and our business development strategies now firmly position us for future success. We look forward to continuing to leverage our superior technology and industry relationships to drive increased market penetration in the rapidly evolving Life Sciences sector.”